Advice
Following an abbreviated submission:
5-aminolevulinic acid (Alacare®) is accepted for use within NHSScotland.
Indication under review: Single use treatment of mild actinic keratoses lesions with a maximum diameter of 1.8 cm on the face and scalp (hairless areas).
Alacare® medicated plaster is another licensed formulation of 5-aminolevulinic acid and may be associated with a small net budget impact.
Download detailed advice619KB (PDF)
Medicine details
- Medicine name:
- 5-aminolevulinic acid (Alacare)
- SMC ID:
- SMC2353
- Indication:
Single use treatment of mild actinic keratoses lesions with a maximum diameter of 1.8 cm on the face and scalp (hairless areas).
- Pharmaceutical company
- Medac Pharma LLP
- BNF chapter
- Skin
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 June 2021